Isolated Central Nervous System Tuberculosis‐Associated Immune Reconstitution Inflammatory Syndrome—Case Report and Literature Review Authors: Mithen Ravisankar, Muniza Bai, Vignesh Kumar Kathiresan, Jefferson Daniel Jawahar, Balamugesh Thangakunam, Angel Miraclin Thirugnanakumar, Elanthenral Sigamani Published: 2026 ABSTRACT ABSTRACTAn immunocompetent young male in his early 20s presented with a 1‐month history of central chest pain, dyspepsia and significant weight loss. Initial evaluation revealed a large, deep oesophageal ulcer and extensive necrotic mediastinal lymphadenopathy. Endobronchial ultrasound‐guided fine‐needle aspiration of the mediastinal nodes confirmed necrotising granulomatous inflammation, suggestive of tuberculosis. Following initiation of anti‐tuberculosis treatment (ATT), he initially showed systemic improvement. However, within 2 weeks, he developed drug‐induced liver injury along with new‐onset focal neurological deficits, including right‐sided hemiparesis and vocal cord palsy. Neuroimaging revealed multiple new intracranial lesions involving the left temporal lobe, right posterior parietal region and brainstem, whilst repeat cross‐sectional imaging of the chest and abdomen was suggestive of interval improvement. A diagnosis of paradoxical isolated central nervous system tuberculosis‐associated immune reconstitution inflammatory syndrome was made. He was managed with high‐dose systemic corticosteroids and a modified hepatoprotective ATT regimen, resulting in clinical improvement.Keywords: CNS TB, immune reconstitution, IRIS Introduction Immune reconstitution inflammatory syndrome (IRIS) is characterised by an exaggerated inflammatory response to pathogens during immunological recovery [1, 2]. It is classified as paradoxical, defined by clinical or imaging deterioration after starting anti‐tuberculosis treatment (ATT) in patients with a known tuberculosis (TB) diagnosis, or unmasking, where an unrecognised TB infection presents with an exaggerated inflammatory response following immune recovery [3]. Although most frequently described in HIV‐infected patients initiating antiretroviral therapy, TB‐IRIS can also occur in HIV‐negative individuals, with an estimated incidence of 2%–23% [1, 3, 4]. Central nervous system (CNS) involvement in TB‐IRIS is rare (0.9%–1.5%) but associated with high mortality (up to 35%) due to intense inflammation within the rigid cranial vault [3, 4, 5, 6]. Paradoxical TB‐IRIS specifically refers to clinical or radiological worsening of pre‐existing lesions or the emergence of new lesions shortly after initial improvement with effective therapy [7, 8]. This case demonstrates the rare occurrence of isolated CNS‐IRIS during treatment of disseminated TB in an immunocompetent host [9, 10, 11]. Case Report A young male student in his early 20s presented with a 1‐month history of stabbing central chest pain, dyspepsia, loss of appetite and unintentional weight loss of 55 pounds. The chest pain was non‐radiating, without any specific aggravating or relieving factors. There was no history of fever, night sweats, cough, expectoration, breathlessness, abdominal pain, nausea, vomiting or dysphagia. He had no significant medical history and no known comorbidities. He had no history of substance use. Upon clinical evaluation, he was haemodynamically stable, and clinical examination was unremarkable. Baseline investigations, including complete blood counts, renal and liver function parameters, were within normal limits. Chest radiography showed mild splaying of the carina with widening of the paratracheal stripe. Computed tomography (CT) of the thorax and abdomen revealed an irregular, heterogeneously enhancing mass lesion (3 × 5 cm) extending from the mid to distal oesophagus, with significantly enlarged mediastinal, para‐oesophageal, para‐aortic and lesser omental lymph nodes (Figure 1A,B). Multiple solid and ground‐glass centrilobular nodules were noted in both lungs, along with several small, irregular, hypodense, non‐enhancing lesions in the liver. The initial differential diagnoses included malignancy (lymphoma or oesophageal cancer), infection (TB, histoplasmosis or aspergillosis) and sarcoidosis. The first row shows the mediastinal window of CT thorax prior to initiation of ATT. (A) Mediastinal lymphadenopathy (white arrow). (B) An irregular, heterogeneously enhancing mass lesion arising from the mid to distal oesophagus (white arrow). The second row shows the mediastinal window images of the CT thorax obtained 2 weeks after initiation of ATT. (C and D) Interval reduction in the size of the mediastinal nodes and resolution of air foci within the soft tissue lesion of the mid to distal oesophagus, respectively (white arrow). Upper gastrointestinal endoscopy revealed a large (5 × 7 cm) deep distal oesophageal ulcer with undermining edges and air bubbling from the base. Multiple biopsies of the ulcer margin were inconclusive, showing only chronic inflammation with lymphocytes and neutrophils present. Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) test done on biopsy samples was negative. Laboratory evaluation revealed a positive interferon‐gamma release assay for TB. Induced sputum testing, including GeneXpert, bacterial cultures and KOH staining, was negative. Serum angiotensin‐converting enzyme levels were within normal limits, and urine histoplasma antigen was negative. To evaluate for underlying immune status, HIV serology and serum immunoglobulin levels were assessed and found to be unremarkable. This was followed by endobronchial ultrasound transbronchial needle aspiration (EBUS‐TBNA) of the mediastinal lymph nodes (stations 4 L, 7 and 4R) that revealed granulomatous inflammation (Figure 2), suggesting a strong possibility of TB, despite negative Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) and cultures. Based on the clinicoradiological and cytological correlation, a diagnosis of disseminated TB was made and he was initiated on weight‐based anti‐tubercular treatment (ATT) with isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E) regimen. (A) EBUS TBNA cytology smears from mediastinal lymph nodes showing granulomatous inflammation. H&E stain. Smears show well‐formed granulomas composed of epithelioid histiocytes admixed with small mature lymphocytes, in a background of polymorphous inflammatory cells including neutrophils. No definite caseating necrosis is identified. Occasional multinucleated giant cells are noted (inset). (B) Cell block sections show occasional granulomas and lymphoid aggregates admixed with blood clot, along with fragments of cartilage and bronchial epithelium. (C and D) Cell block sections from mediastinal lymph node aspirates showing granulomatous inflammation. H&E stain. Sections show well‐formed non‐necrotising granulomas composed of epithelioid histiocytes admixed with small mature lymphocytes. No definite caseating necrosis is identified. The background shows mixed inflammatory infiltrate with scattered neutrophils and lymphoid aggregates. Occasional bronchial epithelial fragments and cartilage are identified. (E and F) Giemsa‐stained cytology smears showing cohesive aggregates of epithelioid histiocytes forming granulomas in a background of mixed inflammatory cells including lymphocytes and neutrophils. No definite necrosis is identified. The cytomorphological features are in keeping with granulomatous inflammation. Two weeks after initiation of ATT, he developed nausea, vomiting, new‐onset hoarseness of voice, nasal regurgitation, right‐sided deviation of the mouth with drooling and dysphagia for both solids and liquids for 5 days. He also reported new onset numbness and weakness in the right upper limb. There was no history of abdominal pain, diarrhoea, fever, headache, neck rigidity, altered sensorium or gait instability. He was fully compliant with ATT. Examination revealed a weak right‐hand grip and muscle power of 4/5 in the right arm and forearm, with right‐sided sensory loss to touch and pain, and uvular deviation to the left. Diagnostic laryngoscopy confirmed left vocal cord palsy. Laboratory investigations demonstrated normal blood counts and renal function, but elevated liver enzymes (AST 241 U/L, ALT 408 U/L) with normal bilirubin levels. The gastrointestinal symptoms and transaminitis were attributed to ATT‐induced liver injury, necessitating temporary discontinuation of ATT. Magnetic resonance imaging (MRI) brain with contrast performed during this deterioration revealed peripherally enhancing T2 heterogeneously hypointense lesions in the left temporal region and medulla, extending to the lower pons and cerebellar peduncle, with significant perilesional oedema, consistent with intracranial TB (Figure 3). Repeat CT imaging of the thorax and abdomen showed an interval decrease in the size of the mediastinal, intraabdominal and para‐aortic nodes with resolution of the previously seen centrilobular nodules in the lungs and the liver lesions (Figure 1C,D). The first row shows images of contrast enhanced MRI brain, demonstrating a T2 heterogeneously enhancing lesion in the left temporal region and the medulla, with surrounding oedema extending to the lower pons (white arrows). The second row shows the interval reduction in the size of the ring‐enhancing of the left temporal lobe and medulla, along with decrease in perilesional oedema (white arrows). The abrupt onset of focal neurological deficits shortly after initiation of effective treatment necessitated consideration of several critical differential diagnoses. (1) Drug‐resistant TB (MDR‐TB): Less likely given initial systemic improvement. (2) Isolated paradoxical CNS TB‐IRIS: Most likely diagnosis, given the clinical deterioration with concurrent regression of primary systemic lesions. (3) Malignancy: Lymphoma was considered based on weight loss and adenopathy but was excluded by prior EBUS‐TBNA results. Due to concurrent drug‐induced liver injury (DILI), standard ATT was withheld and replaced with a hepatoprotective regimen comprising amikacin, levofloxacin, ethambutol and initially linezolid. Brain biopsy and cerebrospinal fluid studies were deferred as MRI brain showed features of raised intracranial pressure. TB‐IRIS was considered the most likely diagnosis given the emergence of new CNS involvement alongside regression of primary systemic lesions. For isolated CNS TB‐IRIS, high‐dose intravenous dexamethasone (6 mg every 6 h) was initiated along with prophylactic antiepileptics. As liver enzymes normalised, isoniazid, rifampicin and pyrazinamide were sequentially reintroduced under close monitoring. Intravenous dexamethasone was subsequently transitioned to oral administration, with a tapering schedule of 2 mg/week. Steroid‐related precautions were followed. He exhibited a marked clinical response to dexamethasone and modified ATT. Voice and swallowing function improved, enabling removal of the nasogastric tube. Muscle strength in the right upper limb normalised. His chest pain resolved, and he reported improvement in appetite along with weight gain. Follow‐up brain MRI performed at 2 weeks demonstrated significant resolution of the brainstem and temporal lobe lesions (Figure 3). He was discharged in a stable condition on a tapering dose of steroids with a plan for 12 months of standard ATT. On follow‐up, EBUS‐TBNA samples were culture positive for Mycobacterium tuberculosis . Discussion This case demonstrates isolated paradoxical CNS TB‐IRIS in an HIV‐negative, immunocompetent patient. Paradoxical IRIS is defined as an abnormal, excessive immune response to M. tuberculosis antigens (viable or nonviable) in patients already receiving effective ATT [1, 2, 3, 8, 12]. Although TB‐IRIS is well‐documented in HIV‐infected patients after initiation of antiretroviral therapy, its occurrence in HIV‐negative, immunocompetent individuals is less frequent, with an estimated incidence of 2%–23% [1, 8, 13]. It is characterised by clinical deterioration despite an initial response to appropriate therapy and a reduction in systemic bacillary load [6, 7]. However, CNS involvement in TB‐IRIS is rare, reported in only 0.9%–1.5% of cases [4, 8]. CNS‐IRIS constitutes a life‐threatening emergency due to the risk of raised intracranial pressure and brain herniation resulting from intense inflammation within the rigid cranial vault [5, 10]. The immunopathogenesis of TB‐IRIS involves an exuberant, dysregulated host inflammatory response, primarily mediated by T‐helper 1 (Th1) cells [1, 12, 14]. In HIV‐negative patients, rapid mycobacterial killing by ATT is hypothesised to cause a substantial release of tuberculin antigens, which then trigger an unregulated inflammatory cascade and result in significant bystander tissue damage [1, 2, 3, 10]. Identified risk factors in HIV‐negative populations include young age, male sex, disseminated or extrapulmonary TB, involvement of multiple sites at presentation, anaemia, baseline lymphopenia and hypoalbuminaemia [1, 3, 4, 14]. Our patient met several of these criteria, presenting at a young age with disseminated disease involving the oesophagus, lungs, liver and lymph nodes. Paradoxical reactions have been described mostly within the first few months after initiation of ATT. However, delayed presentations have also been reported, with the longest documented interval extending up to 10 years post‐treatment [15]. The unique aspect of this case is the isolated neurological crisis that emerged shortly after the patient began anti‐tubercular treatment. The appearance of new intracranial lesions in the medulla explains the patient's specific focal deficits, including vocal cord palsy and dysphagia (reflecting cranial nerve IX and X involvement) and right hemiparesis. Diagnosis of TB‐IRIS remains a diagnosis of exclusion, requiring clinicians to rule out drug‐resistant TB (DR‐TB), treatment non‐adherence, drug malabsorption, drug interactions, drug‐related adverse reactions, secondary infections and malignancies [1, 6, 7, 16]. The hallmark of a paradoxical reaction in this patient was radiological improvement of the mediastinal nodes occurring simultaneously with the development of new brain and brainstem lesions. Management was further complicated by the development of DILI, which required withholding standard hepatotoxic ATT. A hepatoprotective regimen consisting of Amikacin, Levofloxacin and Ethambutol was initiated to maintain antimicrobial coverage during hepatic recovery. High‐dose systemic corticosteroid therapy is the cornerstone of CNS‐IRIS management [1, 2, 10, 14], as it reduces morbidity and hospitalisation by attenuating the host inflammatory response [5, 8]. The patient's marked clinical and radiological improvement following steroid initiation further supported the diagnosis of TB‐IRIS. In our patient, successful management involved dexamethasone with a hepatoprotective ATT regimen, followed by a cautious sequential reintroduction of standard anti‐TB drugs as liver function normalised. For patients with IRIS refractory to corticosteroids, use of immunomodulators including tumour necrosis factor alpha inhibitors (e.g., infliximab), IL‐1 inhibitors, Janus kinase inhibitors and thalidomide have been explored [17] Although not required in our patient due to good response to corticosteroids, such therapies may represent a potential option in steroid‐refractory CNS TB‐IRIS. TB‐IRIS can occur in HIV‐negative immunocompetent patients, particularly in those with disseminated or extrapulmonary disease. In HIV‐negative patients, risk factors for TB‐IRIS include young age, male sex, lymphopenia, hypoalbuminaemia, disseminated or extrapulmonary disease and involvement of multiple sites. Isolated CNS manifestations may paradoxically emerge within 2 weeks to 3 months after starting ATT, even in the absence of prior neurological symptoms. Diagnosis remains one of exclusion. Management of CNS‐IRIS often requires high‐dose systemic corticosteroids and may necessitate a modified ATT regimen if concurrent DILI occurs. This case illustrates that radiological worsening soon after treatment initiation does not necessarily indicate treatment failure. Clinicians should maintain a high index of suspicion for isolated CNS TB‐IRIS in immunocompetent patients, as prompt corticosteroid therapy is essential to prevent permanent neurological disability and mortality. Author Contributions All authors have made substantive contributions to the study, and all authors endorse the data and conclusions. The patient was under the care of M.B. and M.R.: data collection; writing – original draft, review and editing. M.B.: writing original draft, review and editing, supervision. V.K.K., J.D.J. and E.S.: supervision; writing – review and editing. B.T. and A.M.: supervision; critical analysis, writing – review and editing. Funding The authors have nothing to report. Disclosure The authors declared that no Artificial Intelligence (AI)‐Assisted Technology was used for this manuscript. Consent The authors declare that written informed consent was obtained for the publication of this manuscript and accompanying images and attest that the form used to obtain consent from the patient(s) complies with the Journal requirements as outlined in the author guidelines. Conflicts of Interest The authors declare no conflicts of interest. Ravisankar M., Bai M., Kathiresan V. K., et al., “Isolated Central Nervous System Tuberculosis‐Associated Immune Reconstitution Inflammatory Syndrome—Case Report and Literature Review,” Respirology Case Reports 14, no. 9 (2026): e70728, 10.1002/rcr2.70728. Associate Editor: Jeffrey Ng Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.